Aegerion Pharmaceuticals Reports Preliminary 2014 Net Product Sales, Its Outlook for 2015 and Other Business Updates
12 janv. 2015 07h00 HE
|
Aegerion Pharmaceuticals, Inc.
- Company Completes Acquisition of MYALEPT®
- 2014 Total Net Product Sales Expected to be Between $156 and $158 Million, Representing Approximately 220 Percent Growth over 2013
- 2015...
Aegerion Pharmaceuticals Completes Acquisition of MYALEPT(R)
12 janv. 2015 07h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that it has completed the acquisition of MYALEPT® (metreleptin) for injection, an...
Aegerion Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
05 janv. 2015 16h05 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
08 déc. 2014 08h35 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals to Present at the Deutsche Bank BioFEST Conference
21 nov. 2014 08h30 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 21, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
12 nov. 2014 16h10 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Acquires Myalept(TM) From AstraZeneca
06 nov. 2014 02h10 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that it has entered into a definitive agreement with AstraZeneca to acquire...
Aegerion Pharmaceuticals Announces Third-Quarter 2014 Financial Results
30 oct. 2014 16h05 HE
|
Aegerion Pharmaceuticals, Inc.
Company records $43.7 million in net product sales of JUXTAPID®
2014 net product sales guidance revised to between $150 and $160 million
Company generates $8.7 million in cash flow from...
Aegerion Pharmaceuticals to Announce Third-Quarter 2014 Financial Results on Thursday, October 30
27 oct. 2014 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
08 oct. 2014 16h05 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies...